Christopher Chiu

9.7k total citations · 2 hit papers
32 papers, 3.0k citations indexed

About

Christopher Chiu is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Christopher Chiu has authored 32 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Hematology and 11 papers in Molecular Biology. Recurrent topics in Christopher Chiu's work include Multiple Myeloma Research and Treatments (14 papers), Peptidase Inhibition and Analysis (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Christopher Chiu is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Peptidase Inhibition and Analysis (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Christopher Chiu collaborates with scholars based in United States, Netherlands and Spain. Christopher Chiu's co-authors include Douglas Hanahan, Hiroaki Nozawa, Tahamtan Ahmadi, A. Kate Sasser, Niels W.C.J. van de Donk, Henk M. Lokhorst, Sagar Lonial, Tineke Casneuf, Amy Axel and Tuna Mutis and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Christopher Chiu

32 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis

2006 728 citations Christopher Chiu, Douglas Hanahan et al. Proceedings of the National Academy of Sciences profile →
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →

Peers

Christopher Chiu

ONCOL

HEMAT

IMMUN

RNMI

Markus Müschen United States

David R. Stover United States

Claudia Voena Italy

Esther C.W. Breij Netherlands

Michael Hundemer Germany

Owen N. Witte United States

Thomas Kindler Germany

John Powell United States

Gheath Alatrash United States

Elizabeth A. Punnoose United States

Markus Müschen United States

Christopher Chiu

1.1k ×0.7

ONCOL

2.0k ×1.8

984 ×0.9

HEMAT

1.1k ×1.0

IMMUN

150 ×0.4

RNMI

Citations per year, relative to Christopher Chiu Christopher Chiu (= 1×) peers Markus Müschen

Countries citing papers authored by Christopher Chiu

Since Specialization

Citations

This map shows the geographic impact of Christopher Chiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Chiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Chiu more than expected).

Fields of papers citing papers by Christopher Chiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Chiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Chiu. The network helps show where Christopher Chiu may publish in the future.

Co-authorship network of co-authors of Christopher Chiu

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Chiu. A scholar is included among the top collaborators of Christopher Chiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Chiu. Christopher Chiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Tommy, Leonid Gibiansky, Apurvasena Parikh, et al.. (2025). Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma. Clinical Pharmacology & Therapeutics. 117(5). 1437–1450. 1 indexed citations

Gaglione, Erika M., John H. Herrick, Inhye E. Ahn, et al.. (2023). Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Advances. 7(15). 4089–4101. 27 indexed citations

Soong, David S., Catherine Thiéblemont, John Karavitis, et al.. (2023). Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody. Hematological Oncology. 41(S2). 326–328. 2 indexed citations

Li, Tommy, Ida H. Hiemstra, Christopher Chiu, et al.. (2022). Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas. Clinical Pharmacology & Therapeutics. 112(5). 1108–1119. 25 indexed citations

Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. 398(10306). 1157–1169. 212 indexed citations breakdown →

Bahlis, Nizar J., Meletios Α. Dimopoulos, Darrell White, et al.. (2020). Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 34(7). 1875–1884. 158 indexed citations

Mateos, María‐Victoria, Pieter Sonneveld, Vânia Hungria, et al.. (2019). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma Myeloma & Leukemia. 20(8). 509–518. 93 indexed citations

Matas‐Céspedes, Alba, Vanina Rodríguez, Cédric Rossi, et al.. (2019). Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica. 105(4). 1032–1041. 32 indexed citations

Mateos, María‐Victoria, Andrew Spencer, Ajay K. Nooka, et al.. (2019). Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 105(2). 468–477. 43 indexed citations

10.

Usmani, Saad Z., Imran Khan, Christopher Chiu, et al.. (2018). Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma. Experimental Hematology and Oncology. 7(1). 3–3. 12 indexed citations

11.

Krejcik, Jakub, Inger S. Nijhof, Berris van Kessel, et al.. (2017). Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research. 23(24). 7498–7511. 119 indexed citations

12.

Casneuf, Tineke, Xu Steven Xu, Homer Adams, et al.. (2017). Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Advances. 1(23). 2105–2114. 160 indexed citations

13.

Bahlis, Nizar J., Philippe Moreau, Hareth Nahi, et al.. (2017). DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX). Hematological Oncology. 35(S2). 389–389. 3 indexed citations

14.

Nijhof, Inger S., Tineke Casneuf, Berris van Kessel, et al.. (2016). CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 128(7). 959–970. 275 indexed citations

15.

Atwal, Jasvinder K., Christopher Chiu, Deborah L. Mortensen, et al.. (2013). A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo. OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information). 45 indexed citations

16.

Chun, Matthew G. H., Jian‐Hua Mao, Christopher Chiu, Allan Balmain, & Douglas Hanahan. (2010). Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. Proceedings of the National Academy of Sciences. 107(40). 17268–17273. 18 indexed citations

17.

Kainz, K., Kenneth R. Hogstrom, John A. Antolak, et al.. (2004). Dose properties of a laser accelerated electron beam and prospects for clinical application. Medical Physics. 31(7). 2053–2067. 30 indexed citations

18.

Chiu, Christopher. (2002). BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins. The EMBO Journal. 21(23). 6461–6472. 95 indexed citations

19.

Chiu, Christopher, et al.. (2001). Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Therapy. 8(9). 628–635. 58 indexed citations

20.

Chiu, Christopher, et al.. (2000). High energy laser-wakefield collider with synchronous acceleration. Physical Review Special Topics - Accelerators and Beams. 3(10). 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact